Web Content Viewer (JSR 286)

Apria's COPD Monitoring

Monitoring Patients to Optimize Treatment


By routinely monitoring the patient’s status, Apria is able to determine if the patient is responding to the prescribed therapy. Monitoring is also very important in determining patient compliance. Our goal is to work with you to optimize care. Click here to learn how easy it is to set up a patient with Apria services.


Ongoing Overnight Oximetries and Education for Patients Not Qualifying for Oxygen Based on Initial Screening

  • Conducted every 6 months or, per physician’s orders, for up to 24 months
  • Oximetry at rest and during activities of daily living
  • Overnight oximetry
  • Ongoing disease state education


Alpha-1 Advocacy

  • All Alpha-1 patients are partnered with a dedicated advocate
  • Addresses the needs and demands of on-boarding: insurance verification, therapy coverage, financial assistance, and therapy acceptance
  • Individualized patient support, lifestyle adjustments, guidance on local support groups, and therapy adherence
  • Additional resources: dedicated website, Education Library, Consumer Conference Call Series, and Newsletter 

“It is recommended that all subjects with COPD, or asthma characterized by incompletely reversible air flow obstruction should be tested once for AAT deficiency.”1
Statement from the American Thoracic Society and European Respiratory Society



Apria is the only company that offers a complete line of respiratory screening programs including Alpha-1 for your patients with COPD.


Alpha-1 Antitripsyn Deficiency

Key Facts

  • AAT Deficiency is also called Genetic Emphysema or Genetic COPD
  • AAT Deficiency can lead to irreversible and progressive damage of lung tissue
  • The only FDA approved treatment of AAT Deficiency is augmentation therapy or Enzyme Replacement Therapy
  • The only way to identify AAT carriers or deficient patients is through proper testing


  • A simple blood test is required
  • Apria or Coram representatives can help you obtain a complimentary testing kit

Test Results

  • AAT serum levels in micromoles. Micromoles <11 is considered deficient
  • Phenotype and/or Genotype


Click "Next" to see the types and brands of respiratory equipment we have available.


* All equipment trademarks are properties of their respective owners.



  1. American Thoracic Society/European Respiratory Society Statement: Standards for the Diagnosis and Management of Individuals with Alpha-1 Antitrypsin Deficiency. Am J Respir Crit Care Med. 2003 Oct 1; 168(7): 818-900.
  2. Wencker M, Marx A, Konietzko N, Schaefer B, Campbell EJ. Screening for Alpha-1 Pi deficiency in patients with lung diseases. Eur Respir J. 2002 Aug; 20(2): 319-24.

Web Content Viewer (JSR 286)